SuRE™ Technology Screening services
Identification of regulatory DNA elements and non-coding genetic variants that underlie traits and diseases in humans, plants and animals.
.png)
.png)
.png)
Our novel technology in 2 steps
The SuRE method is in essence a strategy to analyze millions of DNA elements for their activity as promoters or enhancers in a single experiment. By analyzing ~300 million DNA elements of ~300bp length, an entire human genome can be analyzed exhaustively at an approximate 30 fold coverage.
The only required input is DNA and once a SuRE library is established it can be analyzed and compared to other DNA sources in the controlled environment of any transfectable cell type. Thus, without the requirement of invasive biopsies, any genome of interest can be analyzed in relevant cell types and under relevant (e.g. stimulatory) conditions.
1
Library Construction
We first construct a plasmid library containing millions of DNA elements. A human genome is randomly sheared, size-selected and cloned into a plasmid library that contains no promoter of its own. These plasmids contain a unique 20bp sequence referred to as a barcode which allows us to uniquely identify and follow each cloned DNA element. This library is characterized (i.e. barcodes are associated to their respective DNA element) by paired-end sequencing.
barcoded plasmid
Fragmented human genome
0.2 - 2 kb
barcoded plasmid
Plasmid library containing > 300 million DNA elements
2
Library Expression Profiling
In step 2, the plasmid library is transfected into a cell type of interest. DNA elements containing promoters or enhancers will transcribe the barcode which can now be detected in the RNA by high-throughput sequencing. By comparing these barcode frequencies with the frequencies in the plasmid library, a quantitative map of promoter and enhancer activity can be constructed for the human genome.
Transfection plasmid library into ~1*10 cells
8
Quantify expressed barcodes
Quantify all barcodes
('input')
Ratio
Promoter and enhancer activity for entire genome
greenbluebarthin.png)
Introducing our experts
We have a team of ten highly skilled and enthusiastic scientists and technicians dedicated to our clients projects. In addition, they work on new developments around our SuRE™ platform to ensure its continuous improvement for pharmaceutical and agricultural applications. The team is led by founder Joris van Arensbergen and biotech entrepreneur Victor Schut.
Recent news
EVENTS
Events - Annogen attending BIOEurope in Munich, November 6–8, 2023
Request a partnering meeting with P. Victor Schut, CBO (victor@annogen.bio) and discuss the applications of:
- SuRE™ human promoters for cell and gene therapy
- CHO genome derived promoters for protein manufacturing, cell culture, and
- AIM™ integration site mapping for cell engineering (allogeneic, cell therapy and cell line generation).
EVENTS
Events - Annogen attending the virtual partnering at Alliance for Regenerative Medicine, October 17-18, 2023
Annogen plays a specific role in providing its SuRE™ human promoters (cell specific and/or inducible) and AIM™ integration mapping for cell engineering (e.g. allogeneic platforms).
Looking forward to connecting with senior executives and top stakeholders to tackle the most pressing issues in cell and gene therapies. Please contact (victor@annogen.bio) to learn more about the Annogen qualified promoters and cell engineering capabilities.
EVENTS
EVENTS -March 2023 Annogen will be attending/partnering at the upcoming Cell and Gene Meeting on the Med
Looking forward to connecting with senior executives and top stakeholders and our partnering meetings. Please reach out through the partnering system or direct (victor@annogen.bio) to learn more about the Annogen qualified promoters and cell engineering capabilities.
NEWS
NEWS -March 2023 Annogen enters Contract Manufacturing market:
AIM™ services and SuRE™ promoters
AIM™ service (Annogen Integration Mapping: integration sites and their expression levels) was introduced in 2022 supporting cell engineering for cell therapy development.
Now it is also available to the contract manufacturing market: manufacturing virus and recombinant protein
Vacancy
Annogen (Amsterdam) is recruiting a
Bioinformatician
We are looking for someone who is enthusiastic about science and has a strong desire to contribute to cutting-edge research. As a Bioinformatician at our organization, you will be responsible for analysing complex biological data sets and developing and implementing computational methods for data analysis.
NEWS
PRESS RELEASE - January 2023 Annogen starts a collaboration with another leading agricultural multinational to research non-coding regulatory DNA using SuRE™ screening technology.
Annogen started a collaboration with another top agricultural science and technology company to test non-coding DNA fragments
NEWS
PRESS RELEASE - April 2022 Annogen signs another collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA using SuRE™ screening technology.
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence the expression of important crop traits. The results are expected to provide possibilities to intentionally upregulate or downregulate the expression of important genes in crops.
NEWS
Novel approach could aid selective breeding in cattle
​
Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical traits, such as productivity or disease tolerance, in livestock.
The study, involving Roslin researchers and their commercial partner Annogen, will focus on identifying sites in cattle DNA linked to important genes for livestock production and welfare.
NEWS
NEWS – Annogen Featured in C2W
​
SuRE technology finds hidden gene regulation. Many diseases are determined by differences in as yet undiscovered gene regulation. Thanks to plasmids and 'barcodes', the SuRE assay can map this relatively easily and extensively for the entire human genome.
​
Read this article by Marysa van den Berg on the C2W website.
Follow our activities on LinkedIn
